Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
11
2020
revised:
04
01
2021
accepted:
13
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Previous studies have shown that melanoma cells produce excessive levels of cytokines, which have various biological roles during melanoma development. The aim of this study was to expand the profile of serum cytokines, chemokines, growth factors, and angiogenic factors that are associated with melanoma, to find more cytokines with abnormal concentrations in melanoma patients, to identify whether the level of cytokines correlated with prognostic variants, such as Breslow thickness and BRAF mutation, and, finally, to find out the cytokines that play important roles during melanoma development. Multiplex immunobead assay technology and 45-plex immunoassays ProcartaPlex™ kits were used to simultaneously compare the levels of cytokines, growth factors, angiogenic factors, and chemokines between the serum of healthy patients ( Compared to the control group, melanoma patients had higher levels of VEGF-A, PDGF-BB, IL-1RA, PIGF-1, IFN- We found that the levels of VEGF-A and PDGF-BB in the serum of both primary and metastatic melanoma patients are elevated. TNF-
Identifiants
pubmed: 33574842
doi: 10.1155/2021/6610769
pmc: PMC7861916
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6610769Informations de copyright
Copyright © 2021 Xu Wang et al.
Déclaration de conflit d'intérêts
The authors declare they have no conflicts of interest.
Références
J Am Coll Surg. 1995 Sep;181(3):193-201
pubmed: 7670677
Surg Oncol Clin N Am. 2015 Apr;24(2):215-27
pubmed: 25769707
Int J Cancer. 2007 Dec 15;121(12):2606-14
pubmed: 17691110
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Oncologist. 2015 Jun;20(6):660-73
pubmed: 26001391
Mol Cancer Ther. 2016 Oct;15(10):2413-2421
pubmed: 27474151
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Invest Ophthalmol Vis Sci. 2012 Oct 01;53(11):6748-55
pubmed: 22930720
Anticancer Res. 2015 Jun;35(6):3537-41
pubmed: 26026122
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
J Am Coll Surg. 1999 Mar;188(3):241-7
pubmed: 10065812
Int J Cancer. 2000 Jun 15;86(6):768-76
pubmed: 10842189
J Clin Oncol. 2019 Nov 10;37(32):2987-2999
pubmed: 31403867
Circulation. 2011 Nov 15;124(20):2243-52
pubmed: 22007074
Br J Haematol. 2003 Oct;123(1):106-9
pubmed: 14510950
Cancer Immunol Res. 2016 Jun;4(6):488-497
pubmed: 27045020
Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90
pubmed: 25200249
J Immunol. 2001 Jun 1;166(11):6483-90
pubmed: 11359798
Melanoma Res. 2005 Jun;15(3):199-204
pubmed: 15917702
J Mol Med (Berl). 2008 Jul;86(7):785-9
pubmed: 18392794
Am J Cancer Res. 2017 Aug 01;7(8):1714-1723
pubmed: 28861327
Melanoma Res. 1995 Feb;5(1):67-8
pubmed: 7734958
Cancer. 1996 Aug 1;78(3):427-32
pubmed: 8697387
J Clin Oncol. 2005 Feb 10;23(5):1011-27
pubmed: 15585754
PLoS One. 2014 Feb 19;9(2):e88952
pubmed: 24586454
Acta Dermatovenerol Alp Pannonica Adriat. 2012;21(2):27-31
pubmed: 23000937
Int J Cancer. 2015 May 15;136(10):2352-60
pubmed: 25353097
Melanoma Res. 1995 Feb;5(1):41-7
pubmed: 7734955
Clin Cancer Res. 2007 Apr 15;13(8):2422-8
pubmed: 17438101
J Exp Med. 2005 Apr 4;201(7):1089-99
pubmed: 15809353
Melanoma Res. 1999 Oct;9(5):445-50
pubmed: 10596910
Nature. 2001 Sep 20;413(6853):271-2
pubmed: 11565020
Mol Ther. 2014 Jul;22(7):1275-1284
pubmed: 24637454